Assessment of verbal memory in Parkinson's disease utilizing a virtual reality-based Rey Auditory Verbal Learning Test.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 Sep 2024
Historique:
received: 28 02 2024
accepted: 29 08 2024
medline: 19 9 2024
pubmed: 19 9 2024
entrez: 18 9 2024
Statut: epublish

Résumé

The Rey Auditory Verbal Learning Test (RAVLT) is a commonly used tool for evaluating verbal learning and memory in neuropsychological assessments. In recent years, we developed a Virtual Reality (VR) adaptation of the RAVLT (VR-RVLT), aiming for increased ecological validity compared to the traditional pen and paper gold standard (GS-RAVLT). Following validation in healthy cohorts, the VR-RAVLT was validated with thirty individuals with Parkinson's Disease (PD) that completed both the GS-RAVLT and the VR- RAVLT. Validity of the VR-RAVLT was evaluated by assessing its construct and discriminant validity, and test-retest reliability, in comparison to the GS-RAVLT. Results of the PD participants were compared to those of 46 previously recruited healthy participants with comparable age and level of education. Main outcome measures derived from the remembered items on the test lists, exhibited significant and comparable correlations between VR-RAVLT and GS-RAVLT, both among healthy participants and PD participants. Likewise, serial position effects were similar for both formats amog the PD participants. Additionally, both formats showed similar discriminatory ability between healthy controls and PD participants, as well as comparable test-retest reliability measures. Taken together, the results suggest that the VR-based RAVLT is equally effective in measuring verbal memory capabilities in individuals with PD as compared to the GS-RAVLT. Certain results indicate that the virtual reality version has the capability to encompass additional factors that might impact memory performance, thereby suggesting an enhanced ecological validity.

Identifiants

pubmed: 39294213
doi: 10.1038/s41598-024-71618-6
pii: 10.1038/s41598-024-71618-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21792

Informations de copyright

© 2024. The Author(s).

Références

Lezak, M. D. et al. Neuropsychological Assessment (Oxford University Press, 2012).
Organization, W. H. Parkinson disease (2022). https://www.who.int/news-room/fact-sheets/detail/parkinson-disease .
Aarsland, D. et al. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13(4), 217–231 (2017).
doi: 10.1038/nrneurol.2017.27 pubmed: 28257128 pmcid: 5643027
Rey, A. Rey auditory verbal learning test (RAVLT). L’Examen Clinique en psychologie (PUF, 1964).
Vakil, E. & Blachstein, H. Rey AVLT: Developmental norms for adults and the sensitivity of different memory measures to age. Clin. Neuropsychol. 11(4), 356–369 (1997).
doi: 10.1080/13854049708400464
Tierney, M. C. et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch. Neurol. 58(10), 1654–1659 (2001).
doi: 10.1001/archneur.58.10.1654 pubmed: 11594925
Tierney, M. C. et al. Use of the Rey Auditory Verbal Learning Test in differentiating normal aging from Alzheimer’s and Parkinson’s dementia. Psychol. Assess. 6(2), 129 (1994).
doi: 10.1037/1040-3590.6.2.129
Chaytor, N., Schmitter-Edgecombe, M. & Burr, R. Improving the ecological validity of executive functioning assessment. Arch. Clin. Neuropsychol. 21(3), 217–227 (2006).
doi: 10.1016/j.acn.2005.12.002 pubmed: 16554143
Sunderland, A., Harris, J. E. & Baddeley, A. D. Do laboratory tests predict everyday memory? A neuropsychological study. J. Verbal Learn. Verbal Behav. 22(3), 341–357 (1983).
doi: 10.1016/S0022-5371(83)90229-3
Lawrence, B. J., Gasson, N. & Loftus, A. M. Prevalence and subtypes of mild cognitive impairment in Parkinson’s disease. Sci. Rep. 6(1), 33929 (2016).
doi: 10.1038/srep33929 pubmed: 27650569 pmcid: 5030649
Goldman, J. G. et al. Cognitive impairment in Parkinson’s disease: A report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. npj Parkinson’s Disease 4(1), 19 (2018).
doi: 10.1038/s41531-018-0055-3 pubmed: 29951580 pmcid: 6018742
Gottlieb, A. et al. Development and validation of virtual reality-based Rey Auditory Verbal Learning Test. Front. Aging Neurosci. 14, 980093 (2022).
doi: 10.3389/fnagi.2022.980093 pubmed: 36185470 pmcid: 9519387
Montreal Cognitive Assessment (MoCA) clinical data. [cited 2024; Available from: https://mocacognition.com/moca-clinic-data/ ].
Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov. Disord. 19(9), 1020–1028 (2004).
doi: 10.1002/mds.20213 pubmed: 15372591
Broeders, M. et al. Cognitive change in newly-diagnosed patients with Parkinson’s disease: A 5-year follow-up study. J. Int. Neuropsychol. Soc. 19(6), 695–708 (2013).
doi: 10.1017/S1355617713000295 pubmed: 23544964
Erdfelder, E., Faul, F. & Buchner, A. GPOWER: A general power analysis program. Behav. Res. Methods Instrum. Comput. 28(1), 1–11 (1996).
doi: 10.3758/BF03203630
Hunter, H. et al. Longitudinal falls data in Parkinson’s disease: Feasibility of fall diaries and effect of attrition. Disabil. Rehabil. 40(19), 2236–2241 (2018).
doi: 10.1080/09638288.2017.1329357 pubmed: 28573883
Ibarretxe-Bilbao, N. et al. Dysfunctions of cerebral networks precede recognition memory deficits in early Parkinson’s disease. Neuroimage 57(2), 589–597 (2011).
doi: 10.1016/j.neuroimage.2011.04.049 pubmed: 21554963
Pellecchia, M. et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson’s disease. Eur. J. Neurol. 21(5), 802–807 (2014).
doi: 10.1111/ene.12137 pubmed: 23551560
Koo, T. K. & Li, M. Y. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J. Chiropr. Med. 15(2), 155–163 (2016).
doi: 10.1016/j.jcm.2016.02.012 pubmed: 27330520 pmcid: 4913118
Pedale, T. et al. Developmental differences in the impact of perceptual salience on short-term memory performance and meta-memory skills. Sci. Rep. 12(1), 1–13 (2022).
doi: 10.1038/s41598-022-11624-8
Pedale, T. & Santangelo, V. Perceptual salience affects the contents of working memory during free-recollection of objects from natural scenes. Front. Hum. Neurosci. 9, 60 (2015).
doi: 10.3389/fnhum.2015.00060 pubmed: 25741266 pmcid: 4330792
Vakil, E. & Blachstein, H. Rey auditory-verbal learning test: Structure analysis. J. Clin. Psychol. 49(6), 883–890 (1993).
doi: 10.1002/1097-4679(199311)49:6<883::AID-JCLP2270490616>3.0.CO;2-6 pubmed: 8300877
Pan, F.-F. et al. A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline. BMC Neurol. 20, 1–8 (2020).
doi: 10.1186/s12883-020-01657-9
Li, X. et al. The role of the Montreal Cognitive Assessment (MoCA) and its memory tasks for detecting mild cognitive impairment. Neurol. Sci. 39(6), 1029–1034 (2018).
doi: 10.1007/s10072-018-3319-0 pubmed: 29550982
Roheger, M., Kalbe, E. & Liepelt-Scarfone, I. Progression of cognitive decline in Parkinson’s disease. J. Parkinson’s Dis. 8(2), 183–193 (2018).
doi: 10.3233/JPD-181306
Biundo, R., Weis, L. & Antonini, A. Cognitive decline in Parkinson’s disease: The complex picture. npj Parkinson’s Disease 2(1), 1–7 (2016).
doi: 10.1038/npjparkd.2016.18
Cerri, S., Mus, L. & Blandini, F. Parkinson’s disease in women and men: What’s the difference?. J. Parkinson’s Dis. 9(3), 501–515 (2019).
doi: 10.3233/JPD-191683
Ramírez-Ruiz, B. et al. Neuropsychological deficits in Parkinson’s disease patients with visual hallucinations. Mov. Disord. Off. J. Mov. Disord. Soc. 21(9), 1483–1487 (2006).
doi: 10.1002/mds.20965
Lyros, E., Messinis, L. & Papathanasopoulos, P. Does motor subtype influence neurocognitive performance in Parkinson’s disease without dementia?. Eur. J. Neurol. 15(3), 262–267 (2008).
doi: 10.1111/j.1468-1331.2007.02046.x pubmed: 18190508
Fornari, L. H. T. et al. Striatal dopamine correlates to memory and attention in Parkinson’s disease. Am. J. Nucl. Med. Mol. Imaging 11(1), 10 (2021).
pubmed: 33688451 pmcid: 7936250
Ibarretxe-Bilbao, N. et al. Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J. Neurol. 255, 1324–1331 (2008).
doi: 10.1007/s00415-008-0885-8 pubmed: 18821043
Junqué, C. et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson’s disease with dementia. Mov. Disord. Off. J. Mov. Disord. Soc. 20(5), 540–544 (2005).
doi: 10.1002/mds.20371
Alegret, M. et al. Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch. Neurol. 58(8), 1223–1227 (2001).
doi: 10.1001/archneur.58.8.1223 pubmed: 11493162
Jozwiak, N. et al. REM sleep behavior disorder and cognitive impairment in Parkinson’s disease. Sleep 40(8), zsx101 (2017).
doi: 10.1093/sleep/zsx101 pubmed: 28645156 pmcid: 5806543
Taylor, A. E., Saint-Cyr, J. & Lang, A. Frontal lobe dysfunction in Parkinson’s disease: The cortical focus of neostriatal outflow. Brain 109(5), 845–883 (1986).
doi: 10.1093/brain/109.5.845 pubmed: 3779372
Fife, D. A., Mendoza, J. L. & Terry, R. The assessment of reliability under range restriction: A comparison of α, ω, and test–retest reliability for dichotomous data. Educ. Psychol. Meas. 72(5), 862–888 (2012).
doi: 10.1177/0013164411430225
Gallagher, J. et al. Validating virtual administration of neuropsychological testing in Parkinson disease: A pilot study. Sci. Rep. 13(1), 16243 (2023).
doi: 10.1038/s41598-023-42934-0 pubmed: 37758767 pmcid: 10533878
Konno, T., Siuda, J. & Wszolek, Z. K. Genetics of Parkinson‘s disease: A review of SNCA and LRRK2. Wiad Lek. 69(3 Pt 1), 328–332 (2016).
pubmed: 27486710
Senbekov, M. et al. The recent progress and applications of digital technologies in healthcare: A review. Int. J. Telemed. Appl. 2020(1), 8830200 (2020).
pubmed: 33343657 pmcid: 7732404

Auteurs

Amihai Gottlieb (A)

Center of Advanced Technologies in Rehabilitation, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. amihai.gottlieb@gmail.com.

Shani Kimel-Naor (S)

Center of Advanced Technologies in Rehabilitation, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

Gabi Zeilig (G)

Department of Neurological Rehabilitation, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
School of Health Professions, Ono Academic College, Kiryat Ono, Israel.

Michal Schnaider Beeri (M)

The Hebert and Jacqueline Krieger Klein Alzheimer's Research Center, Brain Health Institute, Rutgers Health, Newark, NJ, USA.

Meir Plotnik (M)

Center of Advanced Technologies in Rehabilitation, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH